New arrhythmia drug provides only modest efficacy and no clear safety benefits
Tuesday, April 6, 2010 - 04:56
in Health & Medicine
In a rigourous new review of the antiarrhythmic drug dronedarone (Multaq), researchers at the Cedars-Sinai Heart Institute conclude that the controversial drug is only modestly effective and has no clear safety benefits...